Frequently Asked Questions
The market is segmented based on Global mRNA Flu Vaccine Market, By Type (Non-replicating mRNA, In Vivo Self-Replicating mRNA, In Vitro Dendritic Cell Non-Replicating mRNA Vaccine), Product Type (mRNA-1010, mRNA-1020, mRNA-1030), Route of Administration (Intravenous, Intramuscular, Others), End-Users (Clinic, Hospital, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) – Industry Trends and Forecast to 2030.
.
The Global Mrna Flu Vaccine Market size was valued at USD 7.89 USD Billion in 2022.
The Global Mrna Flu Vaccine Market is projected to grow at a CAGR of 9.3% during the forecast period of 2023 to 2030.
The major players operating in the market include Moderna, BioNTech, CureVac, Novavax, Translate Bio, Inovio Pharmaceuticals, Arcturus Therapeutics Holdings, eTheRNA immunotherapies, Valneva, Vaxart, Entos Pharmaceuticals, Abnova Corporation, Anima Biotech, Biontech Pharmaceuticals, Sarepta Therapeutics, iBio, Vaccitech, Alnylam Pharmaceuticals, Beam Therapeutics, Chardan Healthcare Acquisition 2 Corp.
The market report covers data from the U.S., Canada and Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
